ARK Clinical research


Special Health Event


Ark Clinical Research hosted a special health event in collaboration with one of our key sponsors! Through the sponsor’s mobile research unit, pre-screenings were offered to see which patients qualified for two of our type 2 diabetes studies as well as an Ark information booth stationed to provide additional details on our other clinical studies in areas of COVID-19, healthy volunteers, allergy, and metabolic diseases especially to those who did not qualify for the pre-screening.

eli lilly mobile event 1
eli lilly mobile event 2
eli lilly mobile event 3



Covid-19 Drug Prevents Symptomatic Disease in Study, Regeneron Says An antibody drug from Regeneron Pharmaceuticals Inc. reduced the risk of developing symptomatic Covid-19 infection by 81% compared with a placebo in people living with someone infected by the new coronavirus, a study found.



Vaccine trial participant and CNN correspondent’s big reveal. Was it the placebo or the real thing?  Ark Clinical unblinds CNN reporter participating in the Johnson vaccine trial.

Antibody Cocktail


PHASE 3 TRIAL SHOWS REGEN-COV™ (CASIRIVIMAB WITH IMDEVIMAB) ANTIBODY COCKTAIL REDUCED HOSPITALIZATION OR DEATH BY 70% IN NON-HOSPITALIZED COVID-19 PATIENTS.  Ark is performing these studies and after enrolling hundreds of patients , we can attest to the power of these treatments in preventing severe disease.

Johnson & Johnson


Johnson & Johnson’s single-dose vaccine provides strong shield against severe COVID Johnson & Johnson’s one-shot vaccine generated strong protection against Covid-19 in a large, late-stage trial, raising hopes that it can rapidly reshape a stumbling immunization campaign.

Read in Bloomberg:



Because of excellent data with the Regeneron monoclonal antibody study, the 2067 protocol will now be eliminating the placebo arm.

Masks Forever?


Will We Have to Wear Masks Forever? Innovation Advisor Dr. Kenneth Kim Weighs in on the COVID-19 Vaccines.

Latino Community


Dr. Kim shares his thoughts on a ABC vaccine panel on reaching the Latino community this past week.

Single Shot


Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial.



REGENERON REPORTS POSITIVE INTERIM DATA WITH REGEN-COV™ ANTIBODY COCKTAIL USED AS PASSIVE VACCINE TO PREVENT COVID-19.  We have been running this trial for the last several months at Ark Clinical Research, and it is nothing short of amazing results.  We have not seen anyone get sick who entered the trial get sick, and this report shows 100% prevention of symptomatic infection among family who took the drug!

Vaccination Rates


Analysis: My Covid-19 vaccine trial experience remains vital as vaccination rates are lagging.

Interim Phrase


Johnson & Johnson COVID-19 Vaccine Candidate Interim Phase 1/2a Data Published in New England Journal of Medicine.

Neutralizing Antibody


Lilly’s neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 percent for residents.

Covid-19 Vaccine


What’s Happening With Johnson & Johnson’s Covid-19 Vaccine?

FDA Emergency Authorization


CNN article on the Regeneron COVID Treatment Studies – Regeneron asks FDA for emergency authorization of its Covid-19 antibody therapy given to Trump last week.



Dr. Kim’s appearance on Univision – ¿Qué efectividad puede tener el cóctel experimental de medicamentos que le están suministrado a Trump?

Reduced Viral Levels


Regeneron’s REGN-COV2 Antibody Cocktail Reduced Viral Levels and Improved Symptoms in Non-Hospitalized COVID-19 Patients.



Fauci on ‘Highly Specific, Direct’ Therapy for COVID-19.